Who owns Intellia Therapeutics, Inc. (NTL)? Elite investor 13F holders
2 tracked elite investors reported holding Intellia Therapeutics, Inc as of 2026-06-30, including D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Health Care Equipment & Services
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | INTELLIA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 109021025.00 USD | 6443323.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | INTELLIA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 23688068.00 USD | 1400004.000000 | Shares | buy | Original filing |
| Tudor Investment | INTELLIA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.